RXDX-104 program (Ignyta)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameRXDX-104 program (Ignyta)
Drug Alias NameRET tyrosine kinase inhibitors (Nerviano)NMS-616NMS-173
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitorsAnticancer protein kinase inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIgnyta IncNerviano Medical Sciences Srl
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A